Related Experiment Video
Updated: Aug 7, 2026
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
EPSTI1 Is Involved in IL-28A-Mediated Inhibition of HCV Infection
Xianghe Meng1, Darong Yang1, Rong Yu1
1Department of Molecular Medicine of College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha 410082, China.
Abstract:
It has been reported that IFN-λs inhibit HCV replication in vitro. But the mechanisms of how IL-28A conducts antiviral activity and the functions of IL-28A-induced ISGs (IFN-stimulated genes) are not fully understood. In this study, we found that IL-28A has the antiviral effect on HCV life cycle including viral replication, assembly, and release. IL-28A and IFN-α synergistically inhibit virus replication. EPSTI1 (epithelial-stromal interaction 1), one of IL-28A-induced ISGs, plays a vital role in IL-28A-mediated antiviral activity. Furthermore, forced expression of EPSTI1 effectively inhibits HCV replication in the absence of interferon treatment, and knockdown of EPSTI1 contributes to viral enhancement. EPSTI1 can activate PKR promoter and induce several PKR-dependent genes, including IFN-β, IFIT1, OAS1, and RNase L, which is responsible for EPSTI1-mediated antiviral activity.
Insights
Interleukin-28A (IL-28A) inhibits Hepatitis C virus (HCV) replication, assembly, and release. The study identifies epithelial-stromal interaction 1 (EPSTI1) as a key antiviral effector, activating PKR-dependent pathways.
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- Hepatitis C virus (HCV) infection remains a significant global health concern.
- Interferon-lambda (IFN-λ) family, including IL-28A, shows in vitro antiviral activity against HCV.
- The precise mechanisms of IL-28A's antiviral action and the roles of its induced IFN-stimulated genes (ISGs) require further elucidation.
Purpose of the Study:
- To investigate the antiviral mechanisms of IL-28A against the HCV life cycle.
- To identify and characterize the function of IL-28A-induced ISGs in HCV inhibition.
- To explore the synergistic effects of IL-28A with other interferons, such as IFN-α.
Main Methods:
- HCV replication assays in cell culture models.
- Analysis of viral replication, assembly, and release processes.
- Gene expression analysis of IL-28A-induced ISGs.
- Functional studies of EPSTI1, including overexpression and knockdown experiments.
- Reporter assays to assess promoter activity (e.g., PKR promoter).
Main Results:
- IL-28A demonstrated broad antiviral activity against HCV, inhibiting replication, assembly, and release.
- IL-28A and IFN-α exhibited synergistic inhibition of HCV replication.
- Epithelial-stromal interaction 1 (EPSTI1), an IL-28A-induced ISG, was identified as crucial for IL-28A's antiviral effect.
- EPSTI1 overexpression inhibited HCV replication independently of interferon treatment, while EPSTI1 knockdown enhanced viral replication.
- EPSTI1 was found to activate the PKR promoter, inducing downstream PKR-dependent antiviral genes like IFN-β, IFIT1, OAS1, and RNase L.
Conclusions:
- IL-28A effectively inhibits multiple stages of the HCV life cycle.
- EPSTI1 is a key mediator of IL-28A's antiviral activity against HCV.
- EPSTI1 exerts its antiviral function by activating the PKR pathway and inducing downstream antiviral genes.
